Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

Anirudh Tomer, MSca,∗, Daan Nieboer, MScb,c, Monique J. Roobol, PhDc, Anders Bjartell, MD, PhDd, Ewout W. Steyerberg, PhDb,e, Dimitris Rizopoulos, PhDa, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortiumf

*a Department of Biostatistics, Erasmus University Medical Center, Rotterdam, the Netherlands*

*b Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands*

*c Department of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands*

*d Department of Urology, Skåne University Hospital, Malmö, Sweden*

*e Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands*

*f The Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium members presented in Appendix A*

∗Corresponding author (Anirudh Tomer): Erasmus MC, kamer flex Na-2823, PO Box 2040, 3000 CA Rotterdam, the Netherlands. Tel: +31 10 70 43393.

Email addresses: a.tomer@erasmusmc.nl (Anirudh Tomer, MSc), d.nieboer@erasmusmc.nl (Daan Nieboer, MSc), m.roobol@erasmusmc.nl (Monique J. Roobol, PhD), anders.bjartell@med.lu.se (Anders Bjartell, MD, PhD), e.w.steyerberg@lumc.nl (Ewout W. Steyerberg, PhD), d.rizopoulos@erasmusmc.nl (Dimitris Rizopoulos, PhD).

Word count: Main text 3636, Abstract 429.